EUVIMEDEUVIMED entdecken
Crossref

100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States

Siyu Ma

JACC: Cardiovascular Interventions · 2026-03 · 19 (5) · S14

DOI: 10.1016/j.jcin.2026.01.045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-03. Verfasst von Siyu Ma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ma, S. (2026). 100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States. JACC: Cardiovascular Interventions, 19(5), S14. https://doi.org/10.1016/j.jcin.2026.01.045

Vancouver

Ma S. 100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States. JACC: Cardiovascular Interventions. 2026;19(5):S14. doi:10.1016/j.jcin.2026.01.045

BibTeX
@article{Ma2026,
  author = {Ma, Siyu},
  title = {100.45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {S14},
  doi = {10.1016/j.jcin.2026.01.045}
}
Kostenlos starten →